- Company
- Primary biliary cholangitis drug Iqirvo to land in Korea
- by Eo, Yun-Ho Feb 24, 2025 05:51am
- The new drug for primary biliary cholangitis Iqirvo may soon be launched in Korea. According to industry sources, Ipssen Korea is in the process of obtaining marketing authorization from the Ministry of Food and Drug Safety for Iqirvo (elafibranor), a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta (PPAR α, δ) agonist
- Company
- Pricing negotiations for Vocabria+Rekambys combo complete
- by Eo, Yun-Ho Feb 24, 2025 05:51am
- The long-acting HIV drug Vocabria+Rekambys combination therapy is on the verge of being reimbursed in Korea, 2 years after its approval. According to industry sources, GSK Korea recently concluded drug price negotiations with the National Health Insurance Service for the combination therapy of the new HIV drugs Vocabria (cabotegravir) and
- Company
- Asthma drug Tezspire ready for launch
- by Whang, byung-woo Feb 21, 2025 05:56am
- Tezspire (tezepelumab), an anti-TSLP therapy for the treatment of severe asthma, is entering the market with its effectiveness regardless of biomarker status. Although the drug still faces reimbursement hurdle, clinical practices have high hopes. They expect that Tezspire's versatility can change the current treatment paradigm in which drug
- Company
- The aftermath of the prolonged medical care gap continues
- by Moon, sung-ho Feb 20, 2025 05:59am
- Global pharmaceutical companies are launching new blood cancer drugs in Korea one after another, but the situation on site is impeding their access. According to industry sources on the 17th, the the medical school admission expansion policy last year has led to a continued mass resignation of residents, which has disrupted the treatment of b
- Company
- Jeil’s super-antibiotic cefiderocol approved in Korea
- by Nho, Byung Chul Feb 20, 2025 05:59am
- Jeil Pharmaceutical (CEO Seok-je Sung) announced on the 19th that it has received approval from the Ministry of Food and Drug Safety to market the drug Fetroja Inj 1g’ (cefiderocol sulfate tosylate) for the treatment of multidrug-resistant gram-negative bacterial infections. With the approval, adult patients may use Fetroja for the trea
- Company
- Myelofibrosis drug 'Omjjara' attempts at reimb listing
- by Eo, Yun-Ho Feb 20, 2025 05:59am
- 'Omjjara,' a targeted treatment for myelofibrosis, attempts to be added to the National Health Insurance reimbursement list. According to industry sources, GSK Korea submitted a reimbursement application for its new myelofibrosis drug, Omjjara (momelotinib), at the end of last year, and is awaiting to be considered for the Health Insuranc
- Company
- Organon Korea releases first product after spinoff
- by Whang, byung-woo Feb 20, 2025 05:58am
- Organon Korea is launching a new product for the first time since its spin-off in June 2019 and is beginning to expand its influence in earnest. The product, which was unveiled about 3 years after the official launch of the Korean subsidiary, is JADA, a medical device used to control and treat postpartum hemorrhage. The company plans to targe
- Company
- Celltrion’s Prolia and Xgeva biosimilars approved in Europe
- by Chon, Seung-Hyun Feb 19, 2025 05:56am
- On the 18th, Celltrion announced that it had received marketing authorization from the European Commission for Stobocolo and Osenvelt, which are biosimilar versions of Prolia and Xgeva, respectively. The final approval was granted 2 months after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA
- Company
- Osteonoic secures rights to J&J’s bone graft material
- by Lee, Seok-Jun Feb 19, 2025 05:56am
- Osteonic, a company specializing in implants for orthopedic surgery, announced on the 17th that it has secured the domestic rights to DBX Putty, a bone graft material, from Johnson & Johnson Medtech Korea. DBX Putty was developed by MTF Biologics Inc., a US bone graft manufacturer. Johnson & Johnson MedTech holds the global rights to the
- Company
- Next reimb effort for 'Padcev combination therapy'
- by Moon, sung-ho Feb 19, 2025 05:56am
- 'Padcev Combination therapy' has been reported to have changed the urothelial cancer treatment paradigm after 30 years. After its launch in clinical practices in South Korea in the second half of last year, the government has initiated discussion for reimbursement of the therapy. According to the pharmaceutical industry on February 17,
